Innovent Biologics’ ROS1 tyrosine kinase inhibitor (TKI) taletrectinib adipate (Dovbleron) was approved by the National Medical Products Administration, the Chinese equivalent of the FDA, for patients ...

The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the chemotherapy ...

The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The decision was ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...

The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Major Finding: In breast cancer, chemotherapy elicits stronger antitumor responses when administered during estrus. Concept: The estrous cycle alters macrophage infiltration, epithelial-mesenchymal ...

Copyright held by the owner/author(s).

For authors of Research Articles that have been declined for publication at an AACR journal, the AACR offers the corresponding author the option to easily transfer manuscript files and supporting ...

Kris Ann P. Schultz; Suzanne P. MacFarland; Melissa R. Perrino; Sarah G. Mitchell; Junne Kamihara; Alexander T. Nelson; Paige H.R. Mallinger; Jack J. Brzezinski; Kara ...

Machine learning could better stratify patients with metastatic ER-positive, HER2-negative breast cancer who are more or less likely to benefit from CDK4/6 inhibition up front. At Memorial Sloan ...